Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor
aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy
(platinum + paclitaxel) in the treatment of patients with bone metastases cancer with unknown
primary, and provide a better treatment plan for these patients.
1. Primary outcome: Objective response rate (ORR)
2. Secondary outcomes: disease control rate (DCR), duration of remission (DOR),
progression-free disease (PFS), overall survival (OS), median PFS, median OS,
stratification based on clinical features and PD-L1 expression, adverse reactions (AEs),
and quality of life.